Core Viewpoint - Heptagon Pharmaceuticals has entered into a global strategic collaboration with Otsuka Pharmaceutical to jointly develop and commercialize the BCMAxCD3 bispecific T cell engager HBM7020, with a total collaboration value of up to $670 million [1][2]. Group 1: Collaboration Details - The collaboration includes an upfront payment of $47 million and potential milestone payments, with Heptagon eligible for up to $623 million in additional payments upon achieving specific research and commercial milestones [1]. - This marks Heptagon's second major business development (BD) deal with a multinational corporation (MNC) in 2023, following a $4.6 billion deal with AstraZeneca in March [1]. Group 2: Product Information - HBM7020 is a BCMAxCD3 bispecific antibody developed using Heptagon's fully human HBICE bispecific technology and Harbour Mice platform, designed to effectively activate T cells and target specific cells [2]. - The antibody features two binding sites for BCMA, allowing for precise targeting and reduced risk of cytokine release syndrome (CRS), showcasing strong cytotoxic capabilities with broad applications in immunology and oncology [2]. Group 3: Market Position and Achievements - Heptagon has successfully licensed out its bispecific antibody pipeline to international pharmaceutical companies, with total transaction amounts exceeding $1.6 billion, highlighting its global competitiveness [3]. - In Q1 2023, the number of pharmaceutical transactions in China increased by 34% year-on-year, with Heptagon ranking among the top 10 in both global and Chinese pharmaceutical transactions due to its significant deal amounts [3]. - The company has diversified its collaborations across various mechanisms, including ADCs, single/double/multi-antibodies, cell therapies, mRNA, and AI, indicating a successful transition since 2022 [3].

Group 1 - The core viewpoint of the news is that Heptares Therapeutics has entered into a global strategic collaboration agreement with Otsuka Pharmaceutical Co., Ltd. to advance the development of HBM7020, a bispecific T-cell engager for the treatment of autoimmune diseases [1] - Under the agreement, Otsuka is granted exclusive rights to develop, manufacture, and commercialize HBM7020 globally, excluding Greater China [1] - The company is entitled to receive a total of $47 million in upfront and near-term payments, with potential milestone payments of up to $623 million upon achieving specific development and commercialization milestones, along with tiered royalties on future net sales [1] Group 2 - HBM7020 is a bispecific antibody generated using the company's fully human HBICE® dual antibody technology and Harbour Mice® platform, designed to effectively activate T-cells and kill target cells by cross-linking them with BCMA and CD3 on the cell surface [2] - The antibody enhances cell targeting by binding to dual BCMA binding sites and optimizes CD3 activity to reduce cytokine release syndrome (CRS), showing strong cellular activity applicable to immune and tumor diseases [2] - In August 2023, HBM7020 received approval for an Investigational New Drug (IND) application from the National Medical Products Administration (NMPA) in China to initiate Phase I clinical trials for cancer [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 自願公告 有關與大塚就HBM7020戰略合作的業務更新 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）按自 願基準作出，以知會本公司股東及潛在投資者有關本集團的最新業務更新。 和鉑醫藥控股有限公司 本公司董事會（「董事會」）欣然宣佈，本集團已與大塚製藥株式會社（「大塚」）訂立 全球戰略合作協議（「該協議」），以推進用於治療自身免疫性疾病的BCMAxCD3 雙特異性T細胞銜接器HBM7020。根據該協議，大塚獲授予在全球範圍內（不包 括大中華區，即中國大陸、香港、台灣及澳門）開發、製造及商業化HBM7020的 獨家授權。 根據該協議的條款，本公司有權獲得總計47百萬美元的首期及近期付款，並在實 現特定開發及商業化里程碑時，有權獲得高達623百萬美元的潛在里程碑付款， 以及未來淨銷 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年6月19日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

Group 1 - The innovative drug sector has become a focal point in the capital market since 2025, with Hong Kong's innovative drug index showing strong performance, increasing over 60% year-to-date and achieving record trading volumes [1] - Policy incentives and improvements in the industry fundamentals are driving this performance, including accelerated drug approvals and optimization of the medical insurance payment system [2] - The collaboration between domestic companies and international firms, such as the $60.5 billion partnership between 3SBio and Pfizer, highlights the growing international competitiveness of Chinese innovative drugs [2] Group 2 - Despite the long-term positive outlook, short-term volatility risks are present, with some stocks experiencing high price-to-sales ratios and potential profit-taking pressures [3] - The trading congestion in the innovative drug sector reached 3.9% as of June 13, indicating a high level of market activity and potential for significant corrections [3] - Uncertainties in drug development, geopolitical tensions, and currency fluctuations could impact the sector, with risks of clinical trial failures and regulatory changes affecting company valuations [3] Group 3 - The innovative drug index is expected to experience increased differentiation, with leading companies likely to maintain their advantages while weaker firms may lag behind [4] - Investors should focus on performance verification periods and policy developments, such as improvements in the medical insurance payment mechanism and the expansion of the Hong Kong 18A listing [4] - The innovative drug sector is positioned at the intersection of industry cycles and policy benefits, with long-term growth potential driven by international expansion and technological advancements [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 自願公告 股份購回進程及業務更新 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）按自 願基準作出，以知會本公司股東（「股東」）及潛在投資者有關本集團於市場上進行 股份購回的進程及業務的最近更新。 茲提述本公司日期為2025年1月2日及2025年4月10日的公告，內容有關於市場上 購回總額達2.4億港元的股份的計劃，考慮到現時交易價格水平低估了本公司內 在價值、業務前景或近期業務成果。於2025年6月17日，本公司於公開市場購回 股份，涉資近9百萬港元，在2025年對於在香港聯合交易所有限公司上市的生物 科技公司而言，屬重大購回金額。回購進度的加速體現了本公司致力提升股東價 值並對本公司長遠增長前景充滿信心。本公司可根據市場情況授權進一步購回計 劃，惟須遵守 ...

Group 1 - Heptagon Pharma announced the latest progress in its core patent rights protection, with the National Intellectual Property Administration maintaining the validity of its "combination molecule" patent, which involves the use of transgenic animals to produce fully human heavy chain antibodies (HCAb) [1] - The "combination molecule" patent is central to Heptagon Pharma's Harbour Mice® platform, which has established collaborations with several well-known pharmaceutical companies globally, indicating significant commercial value [1] Group 2 - Yunnan Baiyao's JZ-14 capsule, a first-in-class small molecule immunomodulator developed by its subsidiary, has received clinical trial approval, showing significant immunomodulatory and anti-proliferative activity in ulcerative colitis and various tumor models [2] - Successful clinical translation of JZ-14 could fill a gap in the immunomodulation field and expand Yunnan Baiyao's presence in chemical drug innovation [2] Group 3 - Rongchang Bio's product, Taihetai (RC18), has received orphan drug designation from the European Commission for the treatment of myasthenia gravis, which provides various policy supports including scientific advice on development plans and a ten-year market exclusivity post-approval [3] Group 4 - Merck's Clesrovimab (MK-1654) injection application is proposed for priority review by the National Medical Products Administration, aimed at preventing lower respiratory tract infections caused by RSV in newborns and infants entering or born during the RSV season [4] - Clesrovimab's long-acting protective characteristics may alter the current RSV prevention landscape, necessitating attention to its competitive differentiation from vaccines and pricing strategies [4]

| 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年6月13日 | | 827,852,122 | | 18,837,000 | | | 846,689,122 | | 1). 購回股份 (股份被持作庫存股份) | | | -1,100,000 | 0.1329 % | 1,100,000 HKD | | ...

和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 自願公告 法律程序的進展 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 作出，以告知本公司股東及潛在投資者有關本集團知識產權保護工作的最新進展。 本公司董事會（「董事會」）欣然宣佈，針對百奧賽圖（北京）醫藥科技股份有限公 司（「百奧賽圖」）就本公司「結合分子」專利權（專利號：CN201210057668.0，「專 利」）提出的無效宣告請求，國家知識產權局依據《中華人民共和國專利法》第22條 第3款、第26條第3款、第26條第4款及第33條之規定，於2025年6月5日作出審查 決定：維持該專利權有效（「決定」）。該專利涉及一種利用轉基因動物製備全人源 僅重鏈抗體（「HCAb」）的方法。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 承董事會命 和鉑醫藥控股有限公司 主席兼執行董事 王勁松博士 香港 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年6月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | ...